London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It real is bizarre that now the board is almost completely dominated by a few users who are obviously not invested talking the share down. We await an update on board evolution and 2 weekly dosing cohorts.
Ben, those you talk of have very short term horizons. This isn’t a sprint but we may well have a sprint finish!
Ben report them report them report them. This is why our own constructive comments vanish as they do exactly that.
Ben it's not the 'idiots' on the board dropping this sub 40p its the complete lack of interest, yet, from BP.
The comms from Avacta had picked up but now silence again. I think this will come good, very good, but not in the short time so if you are looking for a quick return on investment this is not the share for you.
GLA
First why must everyone be categorised into 'idiots' by which I'm guessing you mean the posters who have allowed themselves to be skeptical and have doubts, and the non 'idiots' who have blind faith that it works and can't even allow themselves even the slightest of doubts.
This is about Avacta and the Market, not the Avacta Bulletin Board and the various words of wisdom that are dispensed hard though that is to be believed.
It might just be that the shares are 40p a throw for a reason?
I agree Thornogson that all sides should be heard, its what makes a BB valuable.
However the sp decline here has nothing to do with the performance of AVA6000 in trial, which is progressing as well as could have been envisaged. It's all to do with shorts who are trying to do here what they did to SAR, as i've posted here multiple times over the past couple of months. Sadly, with the lack of oversight on AIM they are currently winning, which is a sick joke.
I've sold most of mine with a view to reinvesting when the slow crawl down stops, which it assuredly will at some point.
Because ultimately the drug and platform is doing exactly what it was supposed to do
How do you know that Bfd?
You've been allowed to know a bit but I suspect not nearly as much as the specialist European Medical investor who agreed to pay 50p.
Something of a mismatch?
I have doubts, you don't. Like I said 'idiots' and non 'idiots'?
But I agree, Heights style loan deals whilst on paper should bring minimal issues they are in fact a huge Green light for the likes of TW to 'have a go'. Which they do en mass and then it becomes a self fulfilling prophecy.
“It's all to do with shorts “ …..as don’t follow that closely here just wondering if that’s a theory or do you have data to show the level of short positions under the 0.5% threshold. If not would suggest the SP merely reflects that all enthusiasm has been sucked out here due to Company actions.
BFD
" It's all to do with shorts..."
"I've sold most of mine with a view to reinvesting when the slow crawl down stops, which it assuredly will at some point."
Lol. So let me get this right. You sold Avacta shares at a higher price with a view to buying them back at a lower price.
But it's all the shorter's fault!
Rambo: "This is why our own constructive comments vanish".
Who are you referring to in the collective? Who are you working with and why?
Yep you lot are, as again we are back to reporting my posts just because you don't agree with the content.
Remember its not crossing any posting guidelines, and it tends to be the mistakes you learn from rather than the successes, but you idiots carry on stopping discussion on what we can learn collectively from our mistakes.
You might get lucky but thats what it will be on this one, so don't ever kid yourselves it was your investing prowess.....
Reported. 😉
Yep, it’s the .7% short that’s doing all the damage. When someone shows the yank how the RNS machine works, that shorts gonna burn and we will be back to 45p in no time.
I don't think you understand how shorts work
M216 my point was more a general one I know others have experienced themselves. If you post some factual points in response to some FUD expert nonsense and then it disappears from the board it suggests the trolls have reported it deliberately. Funny that. For clarity I don't work for anyone. No games here just a shareholder unlike some others. I was replying to Ben's post I agreed with and used 'our' to include anyone posting constructive comments nothing more. Sadly there is a lot of nonsense and bickering on LSE.
Thornogson
Firstly I don't categorise anybody as idiots or non idiots. It's just plain rude and does nothing to encourage an actual debate.
You are correct, there is a significant mismatch between a European fund paying 50p and the current continuing share price decline.
If you understand statistics at all, you can see the platform is doing what it is meant to be doing. We are seeing a rolled up version of lots of core data. So far it is doing exactly what it is meant to do.
I'm very careful with the words I use. I'm not saying it works full stop. The early indications are that it works for some cancers but it is by no means certain how well yet.
Why anybody would expect any more from a safety trial is beyond me.
So we have moved downwards by about 70% in sp terms whilst the trial has done what it is meant to do.
Plain daft.
Some posters seem to wish to see the sp as the be and all, as if markets were fair, rational and open. They aren't
They also wish to compare Ava6000 to the LFT, a product which never even got to market. Why anybody would do that is also beyond me. It's chalk and cheese.
Bfd: "They also wish to compare Ava6000 to the LFT, a product which never even got to market. Why anybody would do that is also beyond me. It's chalk and cheese."
A couple of things, as I particularly refer back to the LFT.
It did get to market it just never sold. But also on its way to being a flop it was highlighted by AVCT as being the best test in the world with lots of commercial interest with deals being inked, tie ups with other companies, distributors in place at al. So before we knew it was a flop all the data from the science said it was a fantastic world beater. (Bams and Elisa were also heralded as commercial products filling a need in the market.) Also just as relevant, was the constant delay in getting the LFT approved.
The fact that they all flopped is not the issue.
The reason I refer back is the communication about those products.
For whatever reason the communications about how good the products were, never materialised. The constant delays for approval were never explained.
This is exactly how this trial has progressed, constant delays never explained. As a result the veracity of the science can be brought into question as it is following the same pattern.
So rather than say chalk and cheese, right now the comparison is the same.
The basis of my now increasing scepticism, is not just the coms but the fact that the trial had 7 dose increases the last 3 being unexpected,( and almost certainly a 7th not needed, but we had to have anyway), followed by a short 2WD out of the blue announcement with what looks like a delay in the very first reporting timeline.
I honestly don't understand why anyone thinks this is going to plan or exceeding expectations based on the history of how the company reports "progress" with how this seems to be following the same pathway.
Also if it were so good the raise would not have been at 50p. Also, that would have been, if the data was already so good, the bargain of the sentry with buyers falling over themselves to get in, but has fallen another 20%.
Where has the data-rich release been? No peer review remember.
And the silence from CC, because the silence only means that there is nothing to say. You can bet at 40p with another sell off a couple of months away she needs the SP bolstered, so there is no argument for silence.
Anyway, its not about the LFT per se, its about how AVCT communicate to the market and they have disappointed from the get-go and have continued to do so through this trial
These blooming Indian call centres and AI are a nightmare
There is a huge difference between the LFT and Precision that you never highlight. For a large majority of the population, the former was something people didn't want and couldn't care less about, and at the best used them as a box ticking exercise. The cheapest, crappiest test was sufficient. When it comes to treating cancer, this is flipped on its head. Every single cancer sufferer or relative will want the best treatment with the least side effects. So, whilst the avacta lft might have been the best test in the world, that factor was irrelevant and it was never going to be able to compete on price against the chinese mass produced tests. When it comes to precision, unless this is bought out to be buried, then there will be demand.
omg when did the **** hole well and truly fall out of this?
Wyndrum you know that isn't quite true, or even anywhere near the total truth.
Yes the LFT was licensed for professional use and sold a few. and apparently worked effectively for the original covid and variants. However, it was never released for home use in the UK for various reasons, mainly political,which would be my definition of market launch.
So we know that the platform technology actually worked on diagnostics and therapeutics. We know that so far there is a beneficial effect on a small number of trial patients in the real world. So that is as far as the comparison between the two goes.
I'm surprised anybody would see the greater number of cohorts to find a MTD a bad thing, as this simply shows the product is working better than original expectations
Wyn, I am coming up to my second anniversary as an AVCT investor, so the LFT was slightly before my time. However, I am confident that William Tap, Professor Banerji and the other oncologists involved with the trial provide independent and external validation of AVA6000.
AS’s over optimistic timelines are very frustrating, as are the lack of comms. I hope there is an announcement soon regarding the dosing of the third patient in C2 of the two-weekly trial.
Regarding the three later cohorts (5-7) in the three weekly study - if they help establish an optimal dose for the greater good of future patients, then I still see them as a positive.
BFD: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the AffiDX® SARS-CoV-2 antigen lateral flow test has received a CE mark for use as a consumer self-test in the UK and EU.
So maybe it was bit nearer the truth eh?
My point is, all the coms have and can be read as a positive, its just that that interpretation has thus far been misplaced.
And I can now only assume its deliberate, but for the gazillionth time I am not comparing the LFT to AVA6k.
Its the bloody COMS!!!!
(Oh and gje when you say: "There is a huge difference between the LFT and Precision that you never highlight. For a large majority of the population, the former was something people didn't want and couldn't care less about, and at the best used them as a box ticking exercise. The cheapest, crappiest test was sufficient."
Did you post that at the time? or is it now in hindsight you feel brave enough to be so dismissive of the £200 ex china SP expectation of so many here?
Wyndrum you make my point for me.
You have chosen to post from an RNS that came after government policy had stopped any potential marketing of the test for home use. and barely a month before Avacta pulled the product and before Medusa were able to even launch it.
So you are once again far from the whole truth.